Vaccination Was Linked to Less Severe Influenza in Older French Inpatients

Seasonal influenza continues to send older adults to hospital with respiratory failure, shock, and multi-organ stress, even in a country with broad access to vaccination. In this nationwide French cohort, prior influenza vaccination was associated with a lower risk of invasive mechanical ventilation and in-hospital death among adults aged 65 years and older hospitalized with laboratory-confirmed influenza between October 2016 and December 2024, excluding the 2020–2021 period.

The clinical signal matters because hospitalization is not a binary outcome. Among older adults, the biological gap between uncomplicated influenza and a rapidly deteriorating course can be narrow, shaped by frailty, cardiopulmonary reserve, and the host inflammatory response. A vaccine that does not fully prevent infection may still blunt viral burden, limit lower-respiratory involvement, and reduce the cascade that leads to ventilatory failure.

French National Data Capture a Large Older-Adult Cohort

The analysis drew on the French National Health Data System and included 132,443 influenza-associated hospitalizations. Vaccination status came from reimbursed community pharmacy dispensing records, which creates a real-world measure of community vaccine uptake rather than a self-reported estimate. Entropy balancing was used to align vaccinated and unvaccinated groups across sociodemographic features, chronic conditions, pneumococcal vaccination, and COVID-19 vaccination, an important step in a cohort where the vaccinated group was older on average and likely carried a heavier burden of baseline vulnerability.

Among the hospitalized patients, 72,852 were vaccinated and 59,591 were unvaccinated. Mean age was 82.3 years in the vaccinated group and 79.3 years in the unvaccinated group, a difference that would ordinarily bias against the vaccinated cohort if age alone drove severity. Despite that imbalance, the adjusted results consistently pointed in the same direction.

Vaccination was not a shield against admission. It was a partial shield against what happened after admission.

Ventilation and Death Diverged, While ICU Admission Did Not

The clearest separation emerged for respiratory support and mortality. Invasive mechanical ventilation occurred in 2,128 vaccinated hospitalizations, or 2.9%, compared with 2,544 unvaccinated hospitalizations, or 4.3%. The adjusted risk ratio was 0.88, with a 95% confidence interval of 0.83 to 0.93, indicating a lower relative risk of ventilatory escalation among vaccinated older adults.

In-hospital death followed a similar pattern. Death occurred in 6,300 vaccinated hospitalizations, or 8.6%, and 4,952 unvaccinated hospitalizations, or 8.3%, with an adjusted risk ratio of 0.90 and a 95% confidence interval of 0.87 to 0.93. The absolute percentages here are close, but the modeled effect still favored vaccination after adjustment, suggesting that the vaccinated cohort may have entered the hospital with a trajectory less likely to end in fatal respiratory compromise.

The composite severe outcome also favored vaccination modestly, with an adjusted risk ratio of 0.96 and a 95% confidence interval of 0.94 to 0.98. ICU admission, by contrast, did not differ meaningfully between groups; the adjusted risk ratio was 0.99 with a 95% confidence interval of 0.96 to 1.01. In practical terms, vaccination did not appear to prevent critical-care triage once clinicians had already decided that an older patient required ICU-level monitoring, but it may have reduced the likelihood that the respiratory syndrome progressed to invasive ventilation or death.

ICU Trajectories Suggest a Survival Advantage After Critical Illness Begins

The multistate survival analysis adds an important bedside layer to the cohort results. Among patients who reached the ICU, vaccination was associated with a lower hazard of death, with an adjusted hazard ratio of 0.85 and a 95% confidence interval of 0.78 to 0.92. The median time to discharge was also 2 days shorter in vaccinated patients.

A shorter ICU stay can reflect faster resolution of respiratory failure, fewer downstream complications, or a less intense systemic inflammatory response. In influenza, those mechanisms are biologically plausible. Vaccine-induced immunity may not always block infection in older adults, whose immune responses are often weaker, but it can still narrow the peak of viral replication and blunt the cytokine surge that worsens lung injury, hemodynamic instability, and secondary organ dysfunction. Even a small reduction in physiologic injury can matter when reserve is limited.

What the Study Can and Cannot Support

This is not a trial, and it does not prove causality. Residual confounding remains possible in any retrospective study, especially one relying on administrative data and vaccine dispensing records rather than direct immunogenicity testing or detailed bedside physiologic measurements. The analysis also excludes the 2020–2021 period, which limits the continuity of the calendar years captured, though the reasons for that exclusion are built into the study design rather than a flaw in the reported data.

Still, the cohort is large, nationwide, and clinically grounded in hard endpoints. The fact that the benefit appeared most clearly for invasive ventilation and death, rather than for ICU admission itself, is consistent with a vaccine effect that moderates disease severity more than it prevents the decision to intensify care. Older adults often present with heterogeneous influenza trajectories, and vaccine protection in this age group is rarely absolute. Even so, attenuating the slope of illness after hospitalization can alter the outcome that matters most at the bedside.

For French clinicians and health planners, the findings reinforce a familiar but clinically important message: vaccination may not keep every older adult out of the hospital, but it may lower the chance that influenza becomes a ventilator-dependent or fatal illness once admission occurs. The remaining question is not whether influenza vaccination should be pursued in older adults. It is how much of the observed protection can be reproduced across seasons with differing strain virulence, vaccination coverage, and circulating immunity.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by medRxiv (Clinical Preprints).